High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
AbbVie (ABBV) is closing in on a deal to buy Apogee Therapeutics for $10.9 billion in cash, according to a Reuters report citing people familiar with the matter in the Financial Times. The price values Apogee at a roughly 60% premium to its closing share price on Thursday, June 18, a steep markup ...
Ten thousand dollars a month works out to $120,000 a year, an income stream that exceeds the roughly $68,359 in per-capita disposable personal income reported by the Bureau of Economic Analysis for the first quarter of 2026. For many retirees, that level of cash flow would support a lifestyle well above basic needs. The real ... The Retirement Portfolio That Forks Over a $10,000 Check Every Month
(Bloomberg) -- Global stocks are ending a strong week on a cautious note as relief over an interim peace deal between the US and Iran gave way to a focus on the significant hurdles that remain to secure a lasting agreement.Most Read from BloombergRead the 14-Point Draft Memorandum Between the US and IranModi Warns of ‘Shortage of Trust’ Ahead of Trump MeetingTrump Blows Through His Iran Red Lines in Justifying Peace DealUS and Iran Delay Nuclear Talks as Lebanon Clashes WorsenUS Tells ASML It’s
The US Food and Drug Administration said Thursday it is requesting updates to prescribing informatio
In the most recent trading session, AbbVie (ABBV) closed at $216.49, indicating a -2.14% shift from the previous trading day.
AbbVie (NYSE:ABBV) reported positive Phase 3 results for a venetoclax-based combination in untreated chronic lymphocytic leukemia in less-fit patients. The company also received U.S. FDA approval for SKINVIVE by JUVÉDERM for reducing neck lines and improving neck appearance. AbbVie operates at the intersection of large-scale pharmaceuticals and medical aesthetics, with products that span immunology, oncology, neuroscience and cosmetic treatments. The latest data in chronic lymphocytic...
AbbVie Inc. (NYSE:ABBV) is one of the 10 Undervalued Counter Cyclical Stocks to Buy Now. On June 12, 2026, AbbVie Inc. (NYSE:ABBV) announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association 2026 Congress in Stockholm, Sweden. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic […]
Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
For income investors weighing biopharma exposure, the dividend question on AbbVie (NYSE:ABBV) just got a lot easier to answer. The company posted $15.002 billion in Q1 2026 revenue, beating consensus by $284 million, and management raised full-year adjusted EPS guidance to $14.08 to $14.28. With the stock yielding nearly 3%, the question is whether the ... This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie
AbbVie (NYSE:ABBV) has quietly become one of healthcare’s most underrated growth stories. CEO Robert A. Michael told investors after Q1, “We are off to an excellent start in 2026, with first-quarter results exceeding our expectations.” The numbers back him up. Immunology revenue hit $7.29 billion, with Skyrizi up 30.9% and Rinvoq up 23.3%. Yet shares ... AbbVie Stock Will Hit $300 on This Date
Based on the average brokerage recommendation (ABR), AbbVie (ABBV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Explore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure.
Most Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) owners assume they are buying broad market diversification. The latest Schwab fact sheet tells a different story. SCHD’s top 10 holdings now account for 41% of the fund’s $71.6 billion in net assets, well above the roughly 30% top-10 weight typical of large-cap dividend peers. SCHD still earns ... SCHD Now Concentrates 42 Percent of Your Money in Just 10 Stocks. Here Is Who Should Still Own It
Two retirees walk into retirement with the same amount of money. One builds a portfolio that pays $120,000 a year but barely grows. The other settles for $65,000 a year and focuses on dividend growth. At first glance, the first retiree appears to have won. Twenty-five years later, the second retiree may have collected more ... The Retiree Who Chose $65,000 Instead of $120,000 and Ended Up Richer
In the last week, the United States market has stayed flat, yet it has seen a significant increase of 24% over the past year with earnings forecasted to grow by 19% annually. In this context, identifying stocks that are estimated to be undervalued can offer investors potential opportunities for capitalizing on price discrepancies relative to their fair value.
The iShares Core Dividend Growth ETF (NYSEARCA:DGRO) was built for investors who want a paycheck that gets bigger every year, not a yield chase. DGRO tracks the Morningstar US Dividend Growth Index, screening for companies with at least five consecutive years of dividend growth and payout ratios under 75%. The fund pays a roughly 2.2% ... 64 Years of Raises: How DGRO Finds Companies That Never Cut Dividends
Over the last 7 days, the United States market has remained flat, yet it is up 24% over the past year with earnings anticipated to grow by 19% annually in the coming years. In this context of robust growth expectations, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking potential long-term gains.
Now's the time to load up on these high-yielders.
If you are wondering whether AbbVie at around US$227.73 is still offering fair value, the starting point is to understand what the current price actually reflects. The stock has inched up 0.2% over the past week and 9.2% over the last month, while the year to date return is slightly down 0.7% and the 1 year, 3 year and 5 year returns sit at 23.1%, 82.9% and 142.8% respectively. These moves have kept AbbVie on the radar as investors weigh long term performance against current pricing. Recent...
Healthcare has spent 2026 on the sidelines while the rest of the market does the heavy lifting. The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is down around 1% year to date even after a 6% one-month bounce. That stagnation has left a handful of high-margin operators trading at forward multiples that look out of ... 3 Ridiculously Cheap Healthcare Stocks to Buy in June
Paying $2,000 a month in rent is often described as throwing money away. Homeownership, by contrast, is treated as the only reliable path to wealth. Yet under the right conditions, a dividend portfolio large enough to cover your rent can leave you with greater flexibility and, in some cases, a larger net worth than owning ... Why a Dividend Portfolio That Pays Your Rent May Beat Homeownership by $500,000 Over 20 Years
AbbVie (ABBV) closed at $227.73 in the latest trading session, marking a +1.32% move from the prior day.
While the market fixates on the STELARA patent cliff, the rest of the business is quietly accelerating. Excluding the legacy drug, Johnson & Johnson (JNJ) grew in double digits for the quarter. The Innovative Medicine segment absorbed a massive 920 basis point headwind from STELARA, yet still posted 7.4% growth. This is not a company treading water, but a portfolio already hitting its next stride.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
